Telormedix, a Bioggio, Switzerland-based clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has raised CHF7.5m in equity funding.
Founded in October 2007 and led by CEO Johanna Holldack, Telormedix focuses on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases.
The company intends to use the funding to further advance its product candidates through preclinical and clinical trials.
TMX-101, Telormedix’ lead product, is in a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). In addition, the company achieved significant preclinical results in October 2011 for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer. Telormedix also plans to use the funds to support the development of additional promising molecules.